It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Terns Pharmaceuticals Inc. (TERN) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $9.04. The Terns Pharmaceuticals Inc. has recorded 4 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference.
Terns Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $9.04 and fluctuated between $9.38 as its day high and $8.69 as its day low. The current market capitalization of Terns Pharmaceuticals Inc. is $348.15M. A total of 0.14 million shares were traded on the day, compared to an average of 299.01K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, TERN has seen 4 BUY and 3 SELL insider trades, representing the acquisition of 1,793,102 and the disposition of 1,500,000 shares. Over the last 12 months, there were 20 BUYs and 3 SELLs from insiders. Insiders purchased 15,044,548 shares during that period but sold 1,500,000.
In the most recent transaction, ORBIMED ADVISORS LLC bought 137,931 shares of TERN for 7.25 per share on Dec 23. After the transaction, the Director now owns 4,882,854 company shares. In a previous transaction on Dec 23, GORDON CARL L bought 137,931 shares at 7.25 per share. TERN shares that Director owns now total 4,882,854.
Among the insiders who bought shares, Lu Hongbo acquired of 758,620 shares on Dec 23 at a per-share price of $7.25. This resulted in the Director holding 4,340,212 shares of TERN after the transaction. In another insider transaction, Vivo Opportunity, LLC bought 758,620 shares at $7.25 per share on Dec 23. Company shares held by the 10% Owner now total 4,340,212.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for TERN in the last 3 months, the mean price target is $9.00 with high estimates of $14.00 and low estimates of $6.00. In terms of 52-week highs and lows, TERN has a high of $10.67 and a low of $1.45.
As of this writing, TERN has an earnings estimate of -$0.52 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.4 per share and a lower estimate of -$0.7. The company reported an EPS of -$0.55 in the last quarter, which was 14.10% higher than expectations of -$0.64.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TERN is Buy with a score of 4.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.